公开(公告)号：US08198062B2

公开(公告)日：2012-06-12

申请号：US12202119

申请日：2008-08-29

申请人： Timothy Hitchman ,  Christopher L. G. Dayton ,  Katie A. Kline ,  Jonathan Lyon ,  Mark Wall ,  Nelson R. Barton

发明人： Timothy Hitchman ,  Christopher L. G. Dayton ,  Katie A. Kline ,  Jonathan Lyon ,  Mark Wall ,  Nelson R. Barton

IPC分类号： C12N9/20 ,  C12N11/00 ,  C11D3/386 ,  A23J1/00 ,  A61K38/46

CPC分类号： C12N9/20 ,  A23L29/06 ,  A23V2002/00 ,  A61K8/64 ,  A61K8/66 ,  A61K2800/10 ,  A61Q19/00 ,  C11D3/386 ,  C11D3/38681 ,  C12N9/16 ,  C12Y301/01021

摘要： Provided are hydrolases, including lipases, saturases, palmitases and/or stearatases, and polynucleotides encoding them, and methods of making and using these polynucleotides and polypeptides. Further provided are polypeptides, e.g., enzymes, having a hydrolase activity, e.g., lipases, saturases, palmitases and/or stearatases and methods for preparing low saturate or low trans fat oils, such as low saturate or low trans fat animal or vegetable oils, e.g., soy or canola oils.

公开(公告)号：US08674100B2

公开(公告)日：2014-03-18

申请号：US11736635

申请日：2007-04-18

申请人： Carl R. Illig ,  Shelley K. Ballentine ,  Jinsheng Chen ,  Renee Louise DesJariais ,  Sanath K. Meegalla ,  Mark Wall ,  Kenneth Wilson

发明人： Carl R. Illig ,  Shelley K. Ballentine ,  Jinsheng Chen ,  Renee Louise DesJariais ,  Sanath K. Meegalla ,  Mark Wall ,  Kenneth Wilson

IPC分类号： C07D417/12 ,  C07D279/12 ,  C07D413/12 ,  C07D403/12 ,  C07D233/22 ,  C07D405/12 ,  A61K31/535 ,  A61K31/54 ,  A61K31/497 ,  A61K31/445 ,  A61K31/415

CPC分类号： C07D401/12 ,  C07C53/18 ,  C07D233/90 ,  C07D235/24 ,  C07D307/68 ,  C07D401/14 ,  C07D403/12 ,  C07D405/12 ,  C07D491/056

摘要： The invention is directed to compounds of Formula I: wherein Z, X, J, R2 and W are as set forth in the specification, as well as solvates, hydrates, tautomers and pharmaceutically acceptable salts thereof, that inhibit protein tyrosine kinases, especially c-fms kinase. The compounds of formula I are useful for treating a variety of disorders including autoimmune diseases such as rheumatoid arthritis, multiple sclerosis and psoriasis.

摘要翻译： 本发明涉及式I化合物：其中Z，X，J，R 2和W如说明书中所述，以及其抑制蛋白酪氨酸激酶的溶剂合物，水合物，互变异构体和药学上可接受的盐，特别是c -fms激酶。 式I的化合物可用于治疗各种疾病，包括自身免疫性疾病如类风湿性关节炎，多发性硬化和牛皮癣。

公开(公告)号：US20070249593A1

公开(公告)日：2007-10-25

申请号：US11736617

申请日：2007-04-18

申请人： Carl R. Illig ,  Shelley K. Ballentine ,  Jinsheng Chen ,  Renee Louise DesJarlais ,  Sanath K. Meegalla ,  Mark Wall ,  Kenneth Wilson

发明人： Carl R. Illig ,  Shelley K. Ballentine ,  Jinsheng Chen ,  Renee Louise DesJarlais ,  Sanath K. Meegalla ,  Mark Wall ,  Kenneth Wilson

IPC分类号： A61K31/54 ,  C07D285/16

CPC分类号： C07D403/12 ,  C07D401/12 ,  C07D401/14 ,  C07D403/14 ,  C07D405/12 ,  C07D405/14 ,  C07D417/12 ,  C07D417/14

摘要： The invention is directed to compounds of Formula I: wherein Z, X, J, R2 and W are set forth in the specification, as well as solvates, hydrates, tautomers and pharmaceutically acceptable salts thereof, that inhibit protein tyrosine kinases, especially c-fms kinase. Methods of treating autoimmune diseases; and diseases with an inflammatory component; treating metastasis from ovarian cancer, uterine cancer, breast cancer, prostate cancer, lung cancer, colon cancer, stomach cancer, hairy cell leukemia; and treating pain, including skeletal pain caused by tumor metastasis or osteoarthritis, or visceral, inflammatory, and neurogenic pain; as well as osteoporosis, Paget's disease, and other diseases in which bone resorption mediates morbidity including rheumatoid arthritis, and other forms of inflammatory arthritis, osteoarthritis, prosthesis failure, osteolytic sarcoma, myeloma, and tumor metastasis to bone with the compounds of Formula I, are also provided.

摘要翻译： 本发明涉及式I化合物：其中Z，X，J，R 2和W在本说明书中列出，以及溶剂合物，水合物，互变异构体及其药学上可接受的盐，其中 抑制蛋白酪氨酸激酶，特别是c-fms激酶。 治疗自身免疫性疾病的方法 和具有炎症成分的疾病; 治疗卵巢癌，子宫癌，乳腺癌，前列腺癌，肺癌，结肠癌，胃癌，毛细胞白血病的转移; 并治疗疼痛，包括由肿瘤转移或骨关节炎引起的骨骼疼痛，或内脏，炎症和神经源性疼痛; 骨质疏松症，佩吉特氏病和其他疾病，其中骨吸收介导包括类风湿性关节炎和其它形式的炎症性关节炎，骨关节炎，假体衰竭，溶骨性肉瘤，骨髓瘤和肿瘤转移至骨骼的发病率与式I化合物， 也提供。

公开(公告)号：US20050234081A1

公开(公告)日：2005-10-20

申请号：US10515554

申请日：2003-05-28

申请人： Nalin Subasinghe ,  Ehab Khalil ,  Kristi Leonard ,  Farah Ali ,  Heather Hufnagel ,  Jeremy Travins ,  Shelley Ballentine ,  Kenneth Wilson ,  Maxwell Cummings ,  Wenxi Pan ,  Joan Gushue ,  Sanath Meegalla ,  Mark Wall ,  Jinsheng Chen

发明人： Nalin Subasinghe ,  Ehab Khalil ,  Kristi Leonard ,  Farah Ali ,  Heather Hufnagel ,  Jeremy Travins ,  Shelley Ballentine ,  Kenneth Wilson ,  Maxwell Cummings ,  Wenxi Pan ,  Joan Gushue ,  Sanath Meegalla ,  Mark Wall ,  Jinsheng Chen

IPC分类号： C07D333/22 ,  A61K31/381 ,  A61K31/404 ,  A61K31/41 ,  A61K31/416 ,  A61K31/4178 ,  A61K31/4184 ,  A61K31/4188 ,  A61K31/422 ,  A61K31/427 ,  A61K31/428 ,  A61K31/4436 ,  A61K31/4439 ,  A61K31/444 ,  A61K31/4535 ,  A61K31/4709 ,  A61K31/496 ,  A61K31/497 ,  A61K31/506 ,  A61K31/513 ,  A61K31/5377 ,  A61K31/662 ,  A61P1/04 ,  A61P3/10 ,  A61P5/14 ,  A61P5/48 ,  A61P7/00 ,  A61P7/06 ,  A61P7/08 ,  A61P7/10 ,  A61P9/00 ,  A61P9/10 ,  A61P11/00 ,  A61P11/06 ,  A61P13/02 ,  A61P13/12 ,  A61P17/00 ,  A61P17/02 ,  A61P17/06 ,  A61P19/02 ,  A61P19/10 ,  A61P21/04 ,  A61P25/00 ,  A61P25/28 ,  A61P29/00 ,  A61P31/00 ,  A61P31/04 ,  A61P37/00 ,  A61P37/06 ,  A61P37/08 ,  A61P41/00 ,  A61P43/00 ,  C07D333/12 ,  C07D333/38 ,  C07D333/54 ,  C07D409/12 ,  C07D409/14 ,  C07D413/12 ,  C07D413/14 ,  C07D417/12 ,  C07D495/04 ,  C07F7/08 ,  C07F7/10 ,  C07F9/6553 ,  C07D49/02

CPC分类号： C07D417/12 ,  C07D333/38 ,  C07D409/12 ,  C07D409/14 ,  C07D413/12 ,  C07D413/14 ,  C07D495/04 ,  C07F7/0812 ,  C07F9/655345

摘要： Disclosed is a method for treating the symptoms of an acute or chronic disorder mediated by the classical pathway of the complement cascade, comprising administering to a mammal in need of such treatment a therapeutically effective amount of a compound of Formula (I) or a solvate, hydrate or pharmaceutically acceptable salt thereof; wherein R1, R2, R3, R4 and R7 are defined in the specification, Z is SO or SO2, and Ar is an aromatic or heteroaromatic group as defined herein.

摘要翻译： 公开了一种治疗由补体级联的经典途径介导的急性或慢性病症症状的方法，包括向需要这种治疗的哺乳动物施用治疗有效量的式（I）化合物或溶剂合物， 水合物或其药学上可接受的盐; 其中R 1，R 2，R 3，R 4和R 7， 在本说明书中定义，Z是SO或SO 2，Ar是如本文所定义的芳族或杂芳族基团。

公开(公告)号：US08859602B2

公开(公告)日：2014-10-14

申请号：US11736644

申请日：2007-04-18

申请人： Carl R. Illig ,  Shelley K. Ballentine ,  Jinsheng Chen ,  Renee Louise DesJarlais ,  Sanath K. Meegalla ,  Bruce E. Tomczuk ,  Mark Wall ,  Kenneth Wilson

发明人： Carl R. Illig ,  Shelley K. Ballentine ,  Jinsheng Chen ,  Renee Louise DesJarlais ,  Sanath K. Meegalla ,  Bruce E. Tomczuk ,  Mark Wall ,  Kenneth Wilson

IPC分类号： A61K31/4178 ,  C07D405/12 ,  C07D207/34 ,  C07D413/14 ,  C07D401/12 ,  C07D233/90 ,  C07D405/14 ,  C07D401/14 ,  C07D493/08 ,  C07D413/12 ,  C07D409/12

CPC分类号： C07D409/12 ,  C07D207/34 ,  C07D233/90 ,  C07D401/12 ,  C07D401/14 ,  C07D403/12 ,  C07D405/12 ,  C07D405/14 ,  C07D413/12 ,  C07D413/14 ,  C07D493/08 ,  C12N9/99

摘要： The invention is directed to compounds of Formula I: wherein Z, X, J, R2 and W are set forth in the specification, as well as solvates, hydrates, tautomers and pharmaceutically acceptable salts thereof, that inhibit protein tyrosine kinases, especially c-fms kinase. Methods of treating autoimmune diseases; and diseases with an inflammatory component; treating metastasis from ovarian cancer, uterine cancer, breast cancer, prostate cancer, lung cancer, colon cancer, stomach cancer, hairy cell leukemia; and treating pain, including skeletal pain caused by tumor metastasis or osteoarthritis, or visceral, inflammatory, and neurogenic pain; as well as osteoporosis, Paget's disease, and other diseases in which bone resorption mediates morbidity including rheumatoid arthritis, and other forms of inflammatory arthritis, osteoarthritis, prosthesis failure, osteolytic sarcoma, myeloma, and tumor metastasis to bone with the compounds of Formula I, are also provided.

公开(公告)号：US08481564B2

公开(公告)日：2013-07-09

申请号：US13080861

申请日：2011-04-06

申请人： Carl R. Illig ,  Shelley K. Ballentine ,  Jinsheng Chen ,  Renee Louise DesJarlais ,  Sanath K. Meegalla ,  Mark Wall ,  Kenneth Wilson

发明人： Carl R. Illig ,  Shelley K. Ballentine ,  Jinsheng Chen ,  Renee Louise DesJarlais ,  Sanath K. Meegalla ,  Mark Wall ,  Kenneth Wilson

IPC分类号： C07D401/12 ,  C07D401/14 ,  C07D403/12 ,  C07D403/14 ,  A61K31/549 ,  A61K31/506 ,  A61K31/4545 ,  A61K31/444

CPC分类号： C07D403/12 ,  C07D401/12 ,  C07D401/14 ,  C07D403/14 ,  C07D405/12 ,  C07D405/14 ,  C07D417/12 ,  C07D417/14

摘要： The invention is directed to compounds of Formula I: wherein Z, X, J, R2 and W are set forth in the specification, as well as solvates, hydrates, tautomers and pharmaceutically acceptable salts thereof, that inhibit protein tyrosine kinases, especially c-fms kinase. Methods of treating autoimmune diseases; and diseases with an inflammatory component; treating metastasis from ovarian cancer, uterine cancer, breast cancer, prostate cancer, lung cancer, colon cancer, stomach cancer, hairy cell leukemia; and treating pain, including skeletal pain caused by tumor metastasis or osteoarthritis, or visceral, inflammatory, and neurogenic pain; as well as osteoporosis, Paget's disease, and other diseases in which bone resorption mediates morbidity including rheumatoid arthritis, and other forms of inflammatory arthritis, osteoarthritis, prosthesis failure, osteolytic sarcoma, myeloma, and tumor metastasis to bone with the compounds of Formula I, are also provided.

公开(公告)号：US20110195960A1

公开(公告)日：2011-08-11

申请号：US13080861

申请日：2011-04-06

申请人： Carl R. Illig ,  Shelley K. Ballentine ,  Jinsheng Chen ,  Renee Louise DesJarlais ,  Sanath K. Meegalla ,  Mark Wall ,  Kenneth Wilson

发明人： Carl R. Illig ,  Shelley K. Ballentine ,  Jinsheng Chen ,  Renee Louise DesJarlais ,  Sanath K. Meegalla ,  Mark Wall ,  Kenneth Wilson

IPC分类号： A61K31/549 ,  C07D403/12 ,  A61K31/506 ,  C07D417/14 ,  C07D401/14 ,  A61K31/4545 ,  A61K31/444 ,  C07D401/12 ,  A61K31/443 ,  A61K31/4178 ,  A61P35/00 ,  A61P29/00 ,  A61P9/00 ,  A61P1/00 ,  A61P11/00 ,  A61P25/28 ,  A61P25/18 ,  A61P19/00 ,  C12N9/99

CPC分类号： C07D403/12 ,  C07D401/12 ,  C07D401/14 ,  C07D403/14 ,  C07D405/12 ,  C07D405/14 ,  C07D417/12 ,  C07D417/14

摘要： The invention is directed to compounds of Formula I: wherein Z, X, J, R2 and W are set forth in the specification, as well as solvates, hydrates, tautomers and pharmaceutically acceptable salts thereof, that inhibit protein tyrosine kinases, especially c-fms kinase. Methods of treating autoimmune diseases; and diseases with an inflammatory component; treating metastasis from ovarian cancer, uterine cancer, breast cancer, prostate cancer, lung cancer, colon cancer, stomach cancer, hairy cell leukemia; and treating pain, including skeletal pain caused by tumor metastasis or osteoarthritis, or visceral, inflammatory, and neurogenic pain; as well as osteoporosis, Paget's disease, and other diseases in which bone resorption mediates morbidity including rheumatoid arthritis, and other forms of inflammatory arthritis, osteoarthritis, prosthesis failure, osteolytic sarcoma, myeloma, and tumor metastasis to bone with the compounds of Formula I, are also provided.

摘要翻译： 本发明涉及式I化合物：其中Z，X，J，R 2和W在本说明书中列出，以及其抑制蛋白酪氨酸激酶，特别是c-型的溶剂化物，水合物，互变异构体和药学上可接受的盐， fms激酶。 治疗自身免疫性疾病的方法 和具有炎症成分的疾病; 治疗卵巢癌，子宫癌，乳腺癌，前列腺癌，肺癌，结肠癌，胃癌，毛细胞白血病的转移; 并治疗疼痛，包括由肿瘤转移或骨关节炎引起的骨骼疼痛，或内脏，炎症和神经源性疼痛; 骨质疏松症，佩吉特氏病和其他疾病，其中骨吸收介导包括类风湿性关节炎和其它形式的炎症性关节炎，骨关节炎，假体衰竭，溶骨性肉瘤，骨髓瘤和肿瘤转移至骨骼的发病率与式I化合物， 也提供。

公开(公告)号：US20080051402A1

公开(公告)日：2008-02-28

申请号：US11737517

申请日：2007-04-19

申请人： Carl Illig ,  Shelley Ballentine ,  Jinsheng Chen ,  Sanath Meegalla ,  M. Rudolph ,  Mark Wall ,  Kenneth Wilson ,  Renee Desjarlais ,  Carl Manthey ,  Christopher Molloy

发明人： Carl Illig ,  Shelley Ballentine ,  Jinsheng Chen ,  Sanath Meegalla ,  M. Rudolph ,  Mark Wall ,  Kenneth Wilson ,  Renee Desjarlais ,  Carl Manthey ,  Christopher Molloy

IPC分类号： A61K31/454 ,  A61K31/4545 ,  A61K31/496 ,  A61K31/5377 ,  A61P35/00

CPC分类号： A61K31/5377 ,  A61K31/4178 ,  A61K31/454 ,  A61K31/4545 ,  A61K31/496 ,  A61K45/06 ,  A61N5/10 ,  A61N2005/1098 ,  C07D307/68 ,  C07D401/12 ,  C07D401/14 ,  C07D407/12 ,  C07D409/12 ,  C07D409/14 ,  C12N9/99

摘要： A method of reducing or inhibiting kinase activity of C-KIT in a cell or a subject, and the use of such compounds for preventing or treating in a subject a cell proliferative disorder and/or disorders related to C-KIT using a compound of the present invention: or a solvate, hydrate, tautomer or pharmaceutically acceptable salt thereof. The present invention is further directed to methods for treating conditions such as cancers and other cell proliferative disorders.

摘要翻译： 降低或抑制细胞或受试者中C-KIT的激酶活性的方法，以及使用这些化合物在受试者中预防或治疗细胞增殖性疾病和/或与C-KIT相关的病症的方法， 本发明：或其溶剂合物，水合物，互变异构体或其药学上可接受的盐。 本发明还涉及治疗诸如癌症和其它细胞增殖性疾病的病症的方法。

公开(公告)号：US20070149572A1

公开(公告)日：2007-06-28

申请号：US11550077

申请日：2006-10-17

申请人： Shelley Ballentine ,  Christian Baumann ,  Jinsheng Chen ,  Carl Illig ,  Sanath Meegalla ,  M. Rudolph ,  Robert Tuman ,  Mark Wall ,  Kenneth Wilson ,  Dana Johnson

发明人： Shelley Ballentine ,  Christian Baumann ,  Jinsheng Chen ,  Carl Illig ,  Sanath Meegalla ,  M. Rudolph ,  Robert Tuman ,  Mark Wall ,  Kenneth Wilson ,  Dana Johnson

IPC分类号： A61K31/454

CPC分类号： A61K31/4439 ,  A61K31/454 ,  A61K31/497 ,  A61K31/5355 ,  Y10S514/908

摘要： A method of reducing or inhibiting kinase activity of FLT3 in a cell or a subject, and the use of such compounds for preventing or treating in a subject a cell proliferative disorder and/or disorders related to FLT3 using a ompound of the present invention: or a solvate, hydrate, tautomer or pharmaceutically acceptable salt thereof. The present invention is further directed to methods for treating conditions such as cancers and other cell proliferative disorders.

摘要翻译： 一种减少或抑制细胞或受试者中FLT3的激酶活性的方法，以及使用本发明的方法使用这些化合物在受试者中预防或治疗细胞增殖性疾病和/或与FLT3相关的病症：或 其溶剂合物，水合物，互变异构体或其药学上可接受的盐。 本发明还涉及治疗诸如癌症和其它细胞增殖性疾病的病症的方法。

公开(公告)号：US07109354B2

公开(公告)日：2006-09-19

申请号：US10445817

申请日：2003-05-28

申请人： Nalin Subasinghe ,  Ehab Khalil ,  Kristi Leonard ,  Farah Ali ,  Heather Rae Hufnagel ,  Jeremy M. Travins ,  Shelley K. Ballentine ,  Kenneth T. Wilson ,  Maxwell D. Cummings ,  Wenxi Pan ,  Joan Gushue ,  Sanath Meegalla ,  Mark Wall ,  Jinsheng Chen ,  M. Jonathan Rudolph ,  Hui Huang

发明人： Nalin Subasinghe ,  Ehab Khalil ,  Kristi Leonard ,  Farah Ali ,  Heather Rae Hufnagel ,  Jeremy M. Travins ,  Shelley K. Ballentine ,  Kenneth T. Wilson ,  Maxwell D. Cummings ,  Wenxi Pan ,  Joan Gushue ,  Sanath Meegalla ,  Mark Wall ,  Jinsheng Chen ,  M. Jonathan Rudolph ,  Hui Huang

IPC分类号： C07D333/02 ,  C07D333/32

CPC分类号： C07D417/12 ,  C07D333/38 ,  C07D409/12 ,  C07D409/14 ,  C07D413/12 ,  C07D413/14 ,  C07D495/04 ,  C07F7/0812 ,  C07F9/655345

摘要： Disclosed is a method for treating the symptoms of an acute or chronic disorder mediated by the classical pathway of the complement cascade, comprising administering to a mammal in need of such treatment a therapeutically effective amount of a compound of Formula I or a solvate, hydrate or pharmaceutically acceptable salt thereof; wherein R1, R2, R3, R4 and R7 are defined in the specification, Z is SO or SO2, and Ar is an aromatic or heteroaromatic group as defined herein.

摘要翻译： 公开了一种治疗由补体级联的经典途径介导的急性或慢性病症症状的方法，其包括向需要这种治疗的哺乳动物施用治疗有效量的式I化合物或溶剂合物，水合物或 其药学上可接受的盐; 其中R 1，R 2，R 3，R 4和R 7， 在本说明书中定义，Z是SO或SO 2，Ar是如本文所定义的芳族或杂芳族基团。